iSBTc 23rd Annual Meeting

Helen Chen, MD
National Cancer Institute, CTEP

Thomas A. Davis, MD
Celldex Therapeutics, Inc.

Madhav Dhodapkar, MD
The Rockefeller University

Glenn Dranoff, MD
Dana-Farber Cancer Institute

Thomas F. Gajewski, MD, PhD
University of Chicago

Helen E. Heslop, MD
Baylor College of Medicine

W. Martin Kast, PhD
University of Southern California

Greg Lazar, PhD
Xencor, Inc.

William J. Murphy, PhD
University of California Davis, School of Medicine

Martin Oft, MD
Schering-Plough Biopharma (formerly DNAX)

David Raulet, PhD
University of California, Berkeley

Jeffrey Schlom, PhD
National Cancer Institute, NIH

Hideaki Tahara, MD, PhD
University of Tokyo

Giorgio Trinchieri, MD
National Cancer Institute

Max Wicha, MD
University of Michigan

Jon M. Wigginton, MD
Merck & Co., Inc.

Weiping Zou, MD, PhD
University of Michigan

Peter Bross, MD
FDA - Office of Cellular, Tissue, and Gene Therapies

John C. Byrd, MD
The Ohio State University

John R. Desjarlais, PhD
Xencor, Inc.

Madhav Dhodapkar, MD
The Rockefeller University

Glenn Dranoff, MD
Dana-Farber Cancer Institute

Thomas F. Gajewski, MD, PhD
University of Chicago

Michael C.V. Jensen, MD
City of Hope, Beckman Research Institute

W. Martin Kast, PhD
University of Southern California

Ilona Kryczek, PhD
University of Michigan

Martin Oft, MD
Schering-Plough Biopharma (formerly DNAX)

David Raulet, PhD
University of California, Berkeley

Nicholas P. Restifo, MD
National Cancer Institute

Hideaki Tahara, MD, PhD
University of Tokyo

Giorgio Trinchieri, MD
National Cancer Institute

Pierre van der Bruggen, PhD
Ludwig Institute for Cancer Research

Max Wicha, MD
University of Michigan

Jon M. Wigginton, MD
Merck & Co., Inc.

Weiping Zou, MD, PhD
University of Michigan